

Enhanced dopamine D₂ receptor function in hypothalamus and corpus striatum: their role in liver, plasma and in vitro hepatocyte ALDH regulation in ethanol treated rats

K. G. Akash · T. R. Anju · K. T. Peeyush ·
C. S. Paulose

Received: 12 March 2008 / Accepted: 18 May 2008 / Published online: 7 June 2008
© National Science Council Taipei 2008

Abstract Dopamine D₂ receptors are involved in ethanol self-administration behavior and also suggested to mediate the onset and offset of ethanol drinking. In the present study, we investigated dopamine (DA) content and Dopamine D₂ (DA D₂) receptors in the hypothalamus and corpus striatum of ethanol treated rats and aldehyde dehydrogenase (ALDH) activity in the liver and plasma of ethanol treated rats and in vitro hepatocyte cultures. Hypothalamic and corpus striatal DA content decreased significantly ($P < 0.05$, $P < 0.001$ respectively) and homovanillic acid/dopamine (HVA/DA) ratio increased significantly ($P < 0.001$) in ethanol treated rats when compared to control. Scatchard analysis of [³H] YM-09151-2 binding to DA D₂ receptors in hypothalamus showed a significant increase ($P < 0.001$) in B_{max} without any change in K_d in ethanol treated rats compared to control. The K_d of DA D₂ receptors significantly decreased ($P < 0.05$) in the corpus striatum of ethanol treated rats when compared to control. DA D₂ receptor affinity in the hypothalamus and corpus striatum of control and ethanol treated rats fitted to a single site model with unity as Hill slope value. The in vitro studies on hepatocyte cultures showed that 10⁻⁵ M and 10⁻⁷ M DA can reverse the increased ALDH activity in 10% ethanol treated cells to near control level. Sulpiride, an antagonist of DA D₂, reversed the effect of dopamine on 10% ethanol induced ALDH activity in hepatocytes. Our results showed a decreased dopamine concentration with enhanced DA D₂ receptors in the hypothalamus and corpus striatum of ethanol treated rats. Also, increased ALDH was

observed in the plasma and liver of ethanol treated rats and in vitro hepatocyte cultures with 10% ethanol as a compensatory mechanism for increased aldehyde production due to increased dopamine metabolism. A decrease in dopamine concentration in major brain regions is coupled with an increase in ALDH activity in liver and plasma, which contributes to the tendency for alcoholism. Since the administration of 10⁻⁵ M and 10⁻⁷ M DA can reverse the increased ALDH activity in ethanol treated cells to near control level, this has therapeutic application to correct ethanol addicts from addiction due to allergic reaction observed in aldehyde accumulation.

Keywords ALDH · [³H] YM-09151-2 · Dopamine · Hypothalamus · Corpus striatum · Hepatocyte culture

Introduction

Ethanol affects brain function by interacting with multiple neurotransmitter systems, thereby disrupting the delicate balance of neurotransmitters [1]. Apart from GABAergic and glutamatergic systems, there are strong evidences highlighting the importance of the dopaminergic system's involvement in mediating the craving effects of ethanol [2–6]. The rewarding effect of ethanol seems to be related to the activation of dopamine neurons, especially with an increased release of dopamine in the nucleus accumbens [7, 8]. It is assumed that in ethanol dependence, dopamine neurons are sensitized through cues related to drinking. A number of neurochemical pathways have been implicated in ethanol addiction, including the dopamine (DA), serotonin (5-HT), norepinephrine (NE), gamma-aminobutyric acid (GABA), opioid and cannabinoid neurotransmitter systems. The dopaminergic pathway, in particular, is associated with

K. G. Akash · T. R. Anju · K. T. Peeyush · C. S. Paulose (✉)
Molecular Neurobiology and Cell Biology Unit, Centre for
Neuroscience, Department of Biotechnology, Cochin University
of Science and Technology, Cochin 682022, Kerala, India
e-mails: cspaulose@cusat.ac.in; paulosecs@yahoo.co.in

cognitive, endocrine, and motor functions and reinforcement of addictive substances or behaviors [9]. This contributes to the central nervous system (CNS) depression that occurs with prolonged drinking. The brain of ethanol addicts seems to contain abnormalities that reduce the effectiveness of the dopaminergic system. Serotonergic system appears to be involved in ethanol consumption and reinforcement by activating dopaminergic system [10]. The dopamine D₂ receptor is one of the five physiologically distinct dopamine receptors (D₁, D₂, D₃, D₄ and D₅) found on the synaptic membranes of neurons in the brain [11]. High levels of DA D₂ receptors could protect against ethanol addiction [9] and over expression of DA D₂ reduces ethanol self-administration [12]. Since it is reported [13] that DA D₂ receptor has an association with ethanol addiction, the possible role of DA D₂ receptor locus in the etiology of ethanol addiction has been the focus of considerable attention [13]. Dopamine D₃ receptor genes (DA D₃), also in the same class as DA D₂ but with different pharmacological properties [14], are involved in ethanol-seeking behavior [15]. Hypothalamic function is seriously disrupted by ethanol exposure during development [16]. Ethanol is a potent stimulator of hypothalamic β -endorphin, and hence hypothalamus is an important region affected by ethanol consumption [17]. There are evidences that suggest the role of central and autonomic nervous systems in the regulation of hepatic function [18, 19, 20]. However, little is known about neurotransmitters that mediate the effects of the central nervous system on hepatic ALDH activity. ALDH has been advocated as a marker of ethanol intake. The absence or low levels of ALDH may be associated with ethanol-induced flushing or other reactions to ethanol and therefore, with reduced ethanol use [21]. The acetaldehyde produced from ethanol is metabolized quickly to acetate by ALDH [22]. It is reported that ethanol metabolism is impaired by a nonfunctional form of the enzyme aldehyde dehydrogenase [23]. The precise mechanism by which ALDH regulates voluntary ethanol intake is yet to be elucidated. In this study, we investigated the hypothalamic and corpus striatal DA content, DA D₂ receptors and ALDH activity in the liver and plasma of ethanol treated rats and in vitro hepatocyte cultures.

Materials and methods

Chemicals used for the study

Dopamine, Sodium octyl sulphonate, Tris–buffer, homovanillic acid (HVA), NAD⁺, Propionaldehyde, ascorbic acid, pargyline, calcium chloride, Tris–HCl, Perchloric acid, Sodium dihydrogen phosphate, acetonitrile, Sulpiride, rat tail collagen, William's media E, Dithiothreitol (DTT), collagenase type IV, Earle's balanced salts (EBSS) and

Fetal Calf Serum (FCS) used in the present study were purchased from SIGMA Chemical Co., St. Louis, U.S.A. HPLC solvents of HPLC grade were purchased from SRL and Merck India.

Ethylenediamine tetra acetic acid (EDTA), (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) HEPES, Bovine serum albumin (BSA), Sodium Carbonate (Na₂CO₃), NaOH, Potassium sodium tartrate (NaKC₄H₄O₆), MgCl₂, NaCl, KCl, CuSO₄ and pyrazole were purchased from SRL, Merck and Himedia, India.

Animals

Wistar adult rats of 180–200 g body weight purchased from Amrita Institute of Medical Sciences, Cochin were used for this experiment. All animals were housed in separate cages in 12-h light and 12-h dark periods with free access to water/ethanol and food. All animal care and procedures were in accordance with the Committee for the Purpose of Control and Supervision on Experiments on Animals (CPCSEA) and National Institute of Health (NIH) guidelines.

Administration of ethanol and tissue preparation

Rats were given free access to 15% (v/v) (approx. 7.5 g/Kg body wt./day) ethanol for 15 days as per the modified procedure of Pediconi et al. [24]. Controls were given free access to water for 15 days. All control and ethanol treated rats have the access to dry food pellets during these period. The rats were sacrificed by decapitation on the 15th day of the experiment. The body and brain parts were dissected out according to the procedure of Glowinski and Iversen [25]. The tissues were stored at –70°C for various experiments.

Quantification of dopamine by HPLC

Dopamine and the respective metabolite content were assayed according to Paulose et al. [26], using high-performance liquid chromatography (HPLC) integrated with an electrochemical detector (HPLC-ECD) (Shimadzu, Japan) fitted with C18-CLC-ODS reverse-phase column. The tissue from the brain regions were homogenized in 0.4 N perchloric acid. The homogenate was centrifuged at 5,000 × g for 10 min at 4°C (Biofuge stratos Refrigerated Centrifuge, Japan). The clear supernatant filtered through 0.22 μ m HPLC grade filters were used for HPLC analysis. Mobile phase was 75 mM sodium dihydrogen orthophosphate, 1 mM sodium octyl sulphonate, 50 mM EDTA and 7% acetonitrile (pH 3.25), filtered through 0.22 μ m filter (Millipore) and degassed. A Shimadzu pump (model 10 AS) was used to deliver the solvent at a rate of 1.0 ml/min.

Dopamine and the respective metabolite content was identified by using an electrochemical detector (Model 6A, Shimadzu, Japan), with a retention potential of +0.80 V. The peaks were identified by their retention time compared with those of standards and quantitatively estimated using an integrator (Shimadzu, C-R6A-Chromatopac) interfaced with the detector.

Radio receptor assay (Dopamine D₂ receptor binding studies)

Dopamine D₂ receptor binding assay was done according to the modified procedure of Unis et al. [27]. The dissected hypothalamus and corpus striatum were homogenized in 10 volumes of ice cold 50 mM Tris–HCl buffer, along with 1 mM EDTA, 5 mM MgCl₂, 1.5 mM CaCl₂, 120 mM NaCl, and 5 mM KCl pH.7.4. The homogenate was centrifuged at 48,000 × *g* for 30 min. The pellet was washed and recentrifuged with 50 volumes of the buffer at 48,000 × *g* for 30 min. The pellet was suspended in an appropriate volume of buffer. Binding assays in the hypothalamus and corpus striatum were done using different concentrations i.e., 0.25 nM to 2.5 nM of [³H] YM-09151-2 in 50 mM Tris–HCl buffer, 1 mM EDTA, 5 mM MgCl₂, 1.5 mM CaCl₂, 120 mM NaCl, 5 mM KCl with 10 μM pargyline and 0.1% ascorbic acid in a total incubation volume of 300 μl containing 200–300 μg of protein. Specific binding was determined using 5.0 μM unlabelled sulphiride. Competition studies were carried out with 1.0 nM [³H] YM-09151-2 in each tube with unlabelled sulphiride concentrations varying from 10^{−10} to 10^{−3} M. Tubes were incubated at 25°C for 1 h and filtered rapidly through GF/B filters (Whatman). The filters were washed quickly three times with 5.0 ml of ice cold 50 mM Tris buffer, pH 7.4. Bound radioactivity was counted with cocktail-T in a Wallac 1409 liquid scintillation counter. The receptor binding parameters were determined using Scatchard analysis [28].

Analysis of the receptor binding data

Receptor binding parameters analysis

The receptor binding parameters determined using Scatchard analysis [28]. The maximal binding (B_{max}) and equilibrium dissociation constant (K_d) were derived by linear regression analysis by plotting the specific binding of the radioligand on *x*-axis and bound/free on *y*-axis using Sigma plot computer software. The B_{max} is a measure of the total number of receptors present in the tissue and the K_d represents affinity of the receptors for the radioligand. K_d is inversely related to receptor affinity or the “strength”

of binding. Competitive binding data were analysed using non-linear regression curve-fitting procedure (GraphPad PRISM™, San Diego, USA).

Displacement curve analysis

The data of the competitive binding assays are represented graphically with the log of concentration of the competing drug on *x*-axis and percentage of the radioligand bound on the *y*-axis. The steepness of the binding curve can be quantified with a slope factor, often called a Hill slope. A one-site competitive binding curve that follows the law of mass action has a slope of −1.0. The concentration of competitor that competes for half the specific binding was defined as EC₅₀. It is same as IC₅₀. The affinity of the receptor for the competing drug is designated as K_i and is defined as the concentration of the competing ligand that will bind to half the binding sites at equilibrium in the absence of radioligand or other competitors.

Collagen-coating of culture dishes and hepatocyte culture

Sterile rat-tail collagen solution (100 mg/ml in 0.1% acetic acid) was added to each 35 mm culture dish and spread uniformly. After 2 h, the unattached collagen is aspirated out and the dishes are washed thrice with sterile phosphate buffered saline. Finally, sterile Earl’s balanced salt solution (EBSS, Sigma) was added and the dishes were left in the sterile hood till the seeding of cells.

Hepatocytes were isolated from adult male Wistar rats by collagenase perfusion [29]. The liver was perfused in situ with Ca²⁺-free perfusion buffer (pH 7.4) containing 142 mM NaCl, 6.7 mM KCl, 10 mM HEPES, and 5.5 mM NaOH, and then with Ca²⁺ containing collagenase buffer (pH 7.6) containing 67 mM NaCl, 6.7 mM KCl, 100 mM HEPES, 4.76 mM CaCl₂·2H₂O, 66 mM NaOH and Collagenase type IV (0.05%). After perfusion the hepatocytes were dispersed from the perfused liver, filtered through nylon mesh and washed by three centrifugations in EBSS. The final cell pellet was resuspended in William’s Medium E. Cell viability was tested by trypan blue exclusion. The hepatocyte preparation having a viability of >90% as assessed by trypan blue exclusion were chosen for culture. Hepatocytes were plated on rat tail collagen coated dishes at a density of 7 lakhs cells/35 mm culture dish in 1 ml of William’s medium E containing 10% FCS. Cells were allowed to settle and adhere for three hours in medium. After that the plating media was replaced by serum-free William’s medium E containing 10% ethanol, dopamine and sulphiride with concentrations 10^{−7}, 10^{−5} and 10^{−3} M. The cultures were incubated for 24 h at 37°C in 5% CO₂.

Table 1 DA content and its metabolite in the hypothalamus and corpus striatum of control and experimental rats (nmoles/gm wet weight of the tissue)

Region	Animal status	DA	HVA	HVA/DA
Hypothalamus	Control	0.48 ± 0.03	0.04 ± 0.22	0.07 ± 0.01
	Ethanol treated	0.27 ± 0.04*	0.04 ± 0.01	0.17 ± 0.04***
Corpus striatum	Control	4.22 ± 0.62	1.37 ± 0.21	0.33 ± 0.04
	Ethanol treated	0.35 ± 0.07***	2.43 ± 0.17	5.21 ± 2.51***

Values are mean ± S.E.M of 4–6 separate experiments

* $P < 0.05$

*** $P < 0.001$ when compared with control

The contents were determined using HPLC connected with EC detector and the values were integrated Shimadzu chromatopac with standard values

Kinetic studies of aldehyde dehydrogenase from hepatocyte culture cells

Hepatocyte pellets were washed with 0.1 M sodium pyrophosphate buffer, pH 8.4 and suspended in 60 μ l of sodium pyrophosphate buffer and homogenised in an ultrasound sonicator for 15 s. The tubes were centrifuged at $5,000 \times g$ at 4°C for 10 min and the supernatant used for ALDH enzyme assay.

Aldehyde dehydrogenase activity was assayed in homogenate of cerebral cortex, liver and hepatocyte culture by the modified procedure of Gill et al. [30]. ALDH activity was measured using a Shimadzu UV1201 Spectrophotometer at 25°C at 340 nm. 1 ml of assay mixture contained 0.1 M sodium pyrophosphate buffer pH 8.4, 1.0 mM EDTA, and 5.0 mM dithiothreitol, tissue homogenate containing ALDH enzyme, 10 mM pyrazole and 10–200 μ M propionaldehyde. 1.0 mM NAD^+ was added to initiate the reaction. One Unit of ALDH activity was calculated as 1 μ mole of NADH formed/min. The results were expressed as Units/mg protein. Protein concentrations were estimated [31] using bovine serum albumin as standard.

Statistics

Statistical evaluations were performed by Student's *t*-test and ANOVA using InStat (Ver.2.04) computer programme. Linear regression Scatchard plots were made using SIGMA PLOT (Ver 2.03).

Results

Dopamine content of hypothalamus and corpus striatum was decreased in ethanol treated rats

The hypothalamic dopamine concentration of ethanol treated rats was significantly lower ($P < 0.05$) than that of control (Table 1). The homovanillic acid/dopamine (HVA/

DA) ratio in hypothalamus showed a significant increase ($P < 0.001$) in ethanol treated rats when compared to control (Table 1). The striatal dopamine concentration showed a significant decrease and HVA/DA ratio showed a significant increase ($P < 0.001$) in ethanol treated rats when compared to control (Table 1).

Dopamine D_2 receptor function in hypothalamus and corpus striatum were increased in ethanol treated rats

Scatchard analysis of [^3H] YM-09151-2 binding in the hypothalamus of ethanol treated rats showed a significant increase in B_{max} ($P < 0.001$), without any change in K_d when compared to control (Fig. 1; Table 2). This reflected an increased receptor number without any change in affinity. In the corpus striatum of ethanol treated rats, scatchard analysis showed a significant decrease in K_d ($P < 0.05$) without any change in B_{max} compared to




Fig. 1 Scatchard analysis of [^3H] YM-09151-2 against sulpiride in hypothalamus of control and ethanol treated rats. Incubation was done with different concentration, i. e. 0.25 nM to 2.5 nM of [^3H] YM-09151-2 along with 200–300 μ g of protein. 5.0 μ M sulpiride was used to determine the specific binding. Reaction was stopped by rapid filtration through GF/B (Whatman) Filters with ice cold Tris Buffer pH 7.4. Values are representation of 4–6 separate experiments

Table 2 [³H] YM-019151-2 binding parameters in the hypothalamus of control and ethanol treated rats

Experimental status	B _{max} (fmol/mg protein)	K _d (nM)
Control	10.40 ± 0.32	0.76 ± 0.01
Ethanol treated	19.07 ± 0.43***	0.79 ± 0.06

Values are mean ± S.E.M of 4-6 separate experiments

*** *P* < 0.001 when compared with control

Membrane binding assays were done using different concentrations [³H] YM-019151-2 i.e., 0.25 nM–2.5 nM for hypothalamus along with appropriate protein concentrations. Non-specific binding was determined using 50 μM unlabelled sulpiride

control (Fig. 2; Table 3). This showed an increased affinity of D₂ receptors for dopamine.

The binding data were confirmed by competition binding assay with [³H] YM-09151-2 against sulpiride. Dopamine D₂ receptor affinity in the hypothalamus and corpus striatum of control and ethanol treated rats fitted to a single site model with unity as Hill slope value (Figs. 3 and 4; Tables 4 and 5).

ALDH activity of plasma and liver increased in ethanol treated rats

The ALDH activity showed a significant increase in V_{max} (*P* < 0.05) with a decreased Km (*P* < 0.01) in both plasma and liver of ethanol treated rats when compared to the control (Tables 6 and 7). This showed the increased activity of ALDH with greater affinity in ethanol treated rats.




Fig. 2 Scatchard analysis of [³H] YM-09151-2 against sulpiride in corpus striatum of control and ethanol treated rats. Incubation was done with different concentration, i. e. 0.25 nM to 2.5 nM of [³H] YM-09151-2 along with 200-300 μg of protein. 5.0 μM sulpiride was used to determine the specific binding. Reaction was stopped by rapid filtration through GF/B (Whatman) Filters with ice cold Tris-Buffer pH 7.4. Values are representation of 4–6 separate experiments

Table 3 [³H] YM-019151-2 binding parameters in the corpus striatum of control and ethanol treated rats

Experimental status	B _{max} (fmol/mg protein)	K _d (nM)
Control	218.33 ± 20.65	1.32 ± 0.20
Ethanol treated	180.04 ± 21.63	0.92 ± 0.09*

Values are mean ± SEM of 4–6 separate experiments

* *P* < 0.05 when compared with control

Membrane binding assays were done using different concentrations [³H] YM-019151-2 i.e., 0.25 nM to 2.5 nM for corpus striatum along with appropriate protein concentrations

Non-specific binding was determined using 50 μM unlabelled sulpiride

Increased ALDH activity of hepatocytes in ethanol treated rats reversed to near control level in presence of 10⁻⁵ M and 10⁻⁷ M dopamine

The 24 h culture studies in hepatocytes showed a significant increase in ALDH activity (*P* < 0.001) in 10% ethanol treated cells compared to control cells. This increase in activity in ethanol treated cells was reversed to near control level in presence of 10⁻⁵ M and 10⁻⁷ M Dopamine. Sulpiride, an antagonist of DA D₂, reversed the effect of dopamine on 10% ethanol induced ALDH activity in hepatocyte cells (Table 8). This reflected that the reversal of ALDH activity to near control level was mediated by dopamine D₂.

Discussion

The etiology of ethanol dependence is a complex interaction of psychosocial and biologic factors [32]. Dopamine is thought to be important for both the induction and the expression of behavioral sensitization [33, 34]. Dopaminergic activity in the brain has been known to play a pivotal role in mediating drug and ethanol addiction [35]. Studies report that sensitization to ethanol is associated with changes in the dopaminergic system [36]. The human DA D₂ receptor gene is an important candidate gene for ethanol addiction and/or for the modification of its severity [37–40]. Previous studies indicate that prolonged heavy drinking decreases DA transporter binding and disturbs synaptic DA transport [41]. Ethanol acts on dopaminergic neurons, producing long lasting changes on the systems. The decreased DA content with increased HVA/DA turnover rate in the hypothalamus and corpus striatum observed in our study is suggested to be the result of chronic treatment of ethanol as an attempt to stimulate DA receptor function.

Altered central DA function has been implicated as influencing the propensity for ethanol consumption in




Fig. 3 Displacement of [^3H] YM-09151-2 against sulpiride in hypothalamus of control and ethanol treated rats. Competition studies were carried out with 1.0 nM [^3H] YM-09151-2 in each tube with the unlabelled sulpiride concentrations varying from 10^{-10} to 10^{-3} M. The tubes were incubated at 25°C for 1 h and filtered rapidly through GF/B filters (Whatman). The filters were washed quickly by three successive washing with 3.0 ml of ice cold buffer containing 50 mM Tris buffer, pH 7.4. Values are representation of 4–6 separate experiments

humans [42]. Enhanced 5-HT_{2A} receptor status in the hypothalamus and corpus striatum of ethanol treated rats was reported [43]. Ethanol also acts directly through the production of neuroamines that interact with dopaminergic systems [13, 44]. DA receptor antagonists attenuate the locomotor-activating effects of acute ethanol, suggesting an important role of mesolimbic DA neurons in mediating the acute effects of ethanol [45–47]. The decreased brain




Fig. 4 Displacement of [^3H] YM-09151-2 against sulpiride in corpus striatum of control and ethanol treated rats. Competition studies were carried out with 1.0 nM [^3H] YM-09151-2 in each tube with the unlabelled sulpiride concentrations varying from 10^{-10} to 10^{-3} M. The tubes were incubated at 25°C for 1 h and filtered rapidly through GF/B filters (Whatman). The filters were washed quickly by three successive washing with 3.0 ml of ice cold buffer containing 50 mM Tris buffer, pH 7.4. Values are representation of 4–6 separate experiments

Table 4 Binding parameters of [^3H] YM-019151-2 with sulpiride in the hypothalamus of control and ethanol treated rats

Experimental status	Best fit model	fit (Log EC ₅₀)	K _i	Hill slope
Control	One-site	-7.113	7.70×10^{-8}	-0.99
Ethanol treated	One-site	-7.434	8.7×10^{-8}	-0.97

Values are mean of 4–6 separate experiments

Data were fitted with iterative nonlinear regression software (Prism, GraphPad, San Diego, CA)

K_i—The affinity of the receptor for the competing drug. EC₅₀ is the concentration of the competitor that competes for half the specific binding competition studies were carried out with 1.0 nM [^3H] YM-019151-2 in each tube with the unlabelled sulpiride concentrations varying from 10^{-10} to 10^{-3} M for hypothalamus

5-HT content leads to an up regulation of 5-HT_{2A} in brainstem and an increased affinity of these receptors in cerebral cortex [48]. In the present study, scatchard analysis of [^3H] YM-09151-2 binding showed increased DA D₂ receptors in the hypothalamus and increased affinity of DA D₂ receptors in the corpus striatum. The increase in DA D₂ receptors is a compensatory mechanism for the decreased DA content in the hypothalamus. In the corpus striatum no change in receptor number was observed which was compensated by the increased affinity of the DA D₂ receptors to its ligand. The differences between ethanol treated and control rats in disposition of DA D₂ receptors show presynaptic changes in dopamine synthesis and postsynaptic changes in receptor availability during ethanol treatment. It has been reported that development of tolerance seems to be accompanied by changes in neuronal membrane structure which, in turn, affects the function of membrane-bound dopaminergic receptors [49].

The liver is richly innervated and signaling occurs between the liver and brain [50] and the brain plays an important regulatory role in hepatic functions. Liver dysfunction is associated with more extensive brain dysfunction in liver cirrhosis patients [51]. Dysfunction in

Table 5 Binding parameters of [^3H] YM-019151-2 with sulpiride in the corpus striatum of control and ethanol treated rats

Experimental status	Best fit model	fit (Log EC ₅₀)	K _i	Hill slope
Control	One-site	-4.949	1.12×10^{-5}	-0.99
Ethanol treated	One-site	-5.126	0.75×10^{-5}	-0.99

Values are mean of 4–6 separate experiments

Data were fitted with iterative nonlinear regression software (Prism, GraphPad, San Diego, CA)

K_i—The affinity of the receptor for the competing drug

EC₅₀ is the concentration of the competitor that competes for half the specific binding competition studies were carried out with 1.0 nM [^3H] YM-019151-2 in each tube with the unlabelled sulpiride concentrations varying from 10^{-10} to 10^{-3} M for corpus striatum

Table 6 Kinetic parameters— V_{max} and K_m of aldehyde dehydrogenase in the plasma of control and ethanol treated rats

Experimental status	V_{max} (Units/mg protein)	K_m (μ M)
Control	0.17 \pm 0.04	12.50 \pm 0.05
Ethanol treated	0.25 \pm 0.05*	3.69 \pm 0.65**

Values are mean \pm S.E.M. of 4–6 separate experiments

* $P < 0.05$

** $P < 0.01$ when compared with control

Table 7 Kinetic parameters— V_{max} and K_m —of aldehyde dehydrogenase in the liver of control and ethanol treated rats

Experimental status	V_{max} (Units/mg protein)	K_m (μ M)
Control	0.52 \pm 0.04	21.06 \pm 0.40
Ethanol treated	0.69 \pm 0.04*	10.84 \pm 0.05**

Values are mean \pm S.E.M. of 4–6 separate experiments

* $P < 0.05$

** $P < 0.01$ when compared with control

dopaminergic transmission has been associated with craving for ethanol and influencing withdrawal symptoms [52]. It is reported that the DA neuron dysfunction is correlated with change in levels of ALDH expression in human conditions of Parkinsonism and schizophrenia [53]. It is reported that aldehyde dehydrogenase activity is higher in the animals preferring ethanol than in those ones rejecting ethanol [54]. George et al. [55] reported the cerebral cortex and brainstem DA D_2 receptor mediated functional regulation on central and peripheral ALDH enzyme. The chronic ethanol treatment exerted a hypothalamic mediated stimulatory effect on hepatic ethanol metabolizing enzymes [56]. The alterations in the hypothalamic and striatal DA D_2 receptors are suggested to govern regulation of hepatic ALDH through sympathetic innervations. The

decreased dopamine content in hypothalamus and striatum of ethanol treated rats might have resulted in its conversion to 3,4-dihydroxyphenylacetaldehyde (DOPAL), which can act as a substrate for ALDH. Thus the ALDH activity was enhanced to compensate the increased production of DOPAL. The increased ALDH activity in plasma and liver of ethanol treated rats is suggested to be a compensatory action to metabolize the excess DOPAL produced.

The regulation of sympathetic nervous system by various neurotransmitters is well studied. The involvement of the central GABA and 5-HT₂ receptors in the liver regeneration is already reported from our lab [57, 58]. Pyroja et al. [59] reported that an increased 5-HT content and 5-HT_{2C} receptor in the brainstem and cerebral cortex facilitated the active hepatocyte proliferation. The stimulatory role of GABA receptors on insulin secretion in the brainstem through sympathetic system was reported [60]. It was also reported that a decrease in dopamine D_2 receptor function in hypothalamus, brainstem and pancreas differentially regulates pancreatic islets insulin secretion in streptozotocin induced diabetic condition [61]. There is evidence for regulation of brain dopaminergic system on liver Cytochrome P450 (CYP) isoenzymes functions [62]. Developmental alteration in adrenergic regulation on Hepatic Glycogen Phosphorylase using isolated hepatocytes is reported [63]. This supports the effect of catecholamine on hepatic cells. The specific antagonist for each neurotransmitter or its agonist can inhibit the neurotransmitter mediated pathways in cells. Acetylcholine agonist, carbachol stimulated insulin secretion and its inhibition by antagonist atropine in rat pancreatic islets in vitro was reported [64]. Baclofen, GABA_B agonist, triggered DNA synthesis in primary cultures of rat hepatocytes, mediated through the GABA_B receptors [65] were reported highlighting the effect of neurotransmitter

Table 8 Kinetic parameters— V_{max} and K_m —of aldehyde dehydrogenase in the 24 h hepatocyte culture of rats

Cell status	V_{max} (units/mg protein)	K_m (μ M)
Control	6.1 \pm 0.01	26.25 \pm 0.12
10% Ethanol treated	14.5 \pm 0.05@@@	23.5 \pm 0.15
10 ⁻³ M Dopamine + 10% Ethanol treated	2.5 \pm 0.88**	28.17 \pm 2.20***
10 ⁻⁵ M Dopamine + 10% Ethanol treated	5.7 \pm 0.57***	26.67 \pm 2.21
10 ⁻⁷ M Dopamine + 10% Ethanol treated	4.0 \pm 1.16***	23.33 \pm 0.83
10 ⁻³ M Dopamine + Sulpiride +10% Ethanol treated	14.667 \pm 0.67@@@	25.0 \pm 0.0*
10 ⁻⁵ M Dopamine + Sulpiride +10% Ethanol treated	14.067 \pm 0.88@@@	27.5 \pm 2.50*
10 ⁻⁷ M Dopamine + Sulpiride +10% Ethanol treated	12.333 \pm 0.88@@@	25.83 \pm 0.44**

Values are mean \pm S.E.M. of 4–6 separate experiments

Each experimental group contains 8 groups of rats

@@@ $P < 0.001$ when compared with control

* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ when compared with ethanol treated

The ALDH enzyme activity was measured using a Shimadzu UV1201 Spectrophotometer at 25°C at 340 nm

agonist on hepatic functions. β -adrenergic receptors mediated positive regulation on islet cell proliferation and insulin secretion in vitro was also reported [66]. The culture studies showed that at 10^{-5} M and 10^{-7} M dopamine concentrations, the ALDH enzyme activity was reduced to near normal level. Sulpiride, an antagonist of DA D₂, along with dopamine showed a reversal of the effect shown by dopamine on 10% ethanol treated cells. Changes in the ALDH activity levels in culture appear to be modulated by the DA mediated enzyme regulation. Our results showed that there is a decreased dopamine content with enhanced DA D₂ receptors in the hypothalamus and corpus striatum of ethanol treated rats compared to control. Also, increased ALDH was observed in the plasma and liver of ethanol treated rats and in vitro hepatocyte cultures treated with 10% ethanol. Since the administration of 10^{-5} M and 10^{-7} M DA can reverse the increased ALDH activity in ethanol treated cells to near control level, this has therapeutic application to correct ethanol addicts from addiction.

Acknowledgements This work was supported by research grant from DST, DAE, ICMR, DBT Government of India to Dr. C. S Paulose.

References

1. Faingold CL, N'Gouemo P, Riaz A (1998) Alcohol and neurotransmitter interactions—from molecular to integrative effects. *Prog Neurobiol* 55:509–535
2. Franken IH, Booij J, van den Brink W (2005) The role of dopamine in human addiction : from reward to motivated attention. *Eur J Pharmacol* 526:199–206
3. Grace AA (2000) The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. *Addiction* 95:119–128
4. Noble EP (1996) Alcoholism and the dopaminergic system: a review. *Addict Biol* 1:333–348
5. Spanagel R, Weiss F (1999) The dopamine hypothesis of reward: past and current status. *Trends Neurosci* 22:521–527
6. Volkow ND, Fowler JS, Wang GJ (2003) Positron emission tomography and single-photon emission computed tomography in substance use research. *Semin Nucl Med* 33:114–128
7. Berridge KC, Robinson TE (1998) What is the role of dopamine in reward hedonic impact, reward learning, or incentive salience. *Brain Res Rev* 28:309–369
8. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. *Proc Natl Acad Sci USA* 85:5274–5278
9. Volkow ND, Wang GJ, Begleiter H, Porjesz B, Fowler JS, Telang F, Wong C, Ma Y, Logan J, Goldstein R, Alexoff D, Thanos PK (2006) High levels of dopamine D2 receptors in unaffected members of alcoholic families: possible protective factors. *Arch Gen Psy* 63:999–1008
10. Koob GF, Weiss F (1992) Neuropharmacology of cocaine and ethanol dependence. In: Galanter M (ed) *Recent developments in alcoholism*, vol 10. pp 201–233
11. Mahan L, Burch R, Monsma F, Sibley D (1990) Expression of striatal D₁ dopamine receptors coupled to inositol phosphate production and Ca²⁺ mobilization in *Xenopus* oocytes. *Proc Natl Acad Sci* 87:2196–2200
12. Thanos PK, Volkow ND, Freimuth P, Umegaki H, Ikari H, Roth G, Ingram DK, Hitzemann R (2001) Overexpression of dopamine D2 receptors reduces alcohol self-administration. *J Neurochem* 78:1094–1103
13. Blum K, Noble EP, Sheridan PJ, Montgomery A, Ritchie T, Jagadeeswaran P, Nogami H, Briggs AH, Cohn JB (1990) Allelic association of human dopamine D₂ receptor gene in alcoholism. *JAMA* 263:2055–2060
14. Lee Min-Seo AB, Sung-Ho Ryu (2002) No association between the dopamine D3 receptor gene and Korean alcohol dependence. *Psychiatr Genet* 12:173–176
15. Heidbreder CA, Andreoli M, Marcon C, Thanos PK, Ashby CR, Gardner EL (2004) Role of dopamine D₃ receptors in the addictive properties of alcohol. *Drugs Today* 40:355–365
16. Kelly SJ (1995) Alcohol exposure during development alters hypothalamic neurotransmitter concentrations. *J Neural Transm* 103:55–67
17. Reddy BV, Sarkar DK (1993) Effect of alcohol, acetaldehyde, and salsolinol on β -endorphin secretion from the hypothalamic neurons in primary cultures. *Alcohol Clin Exp Res* 17:1261–1267
18. Jungermann K, Stumpel F (1999) Role of hepatic, intrahepatic and hepatoenteral nerves in the regulation of carbohydrate metabolism and hemodynamics of the liver and intestine. *Hepatogastroenterology* 46:1414–1417
19. Lutt WW (1983) Afferent and efferent neural roles in liver function. *Prog Neurobiol* 21:323–348
20. Shimazu T (1981) Central nervous system regulation of liver and adipose tissue metabolism. *Diabetologia* 20:343–356
21. Narelle K, Hansell, Dona P, Andrew CH, Nicholas G, Martin JB, Whitfield (2005) Erythrocyte aldehyde dehydrogenase activity: lack of association with alcohol use and dependence or alcohol reactions in Australian twins. *Alcohol Alcohol* 40(5):343–348
22. Eriksson CJP (1973) Ethanol and acetaldehyde metabolism in rat strains genetically selected for their ethanol preference. *Biochem Pharmacol* 22:2283–2292
23. Wall TL, Ehlers CL (1995) Genetic influences affecting alcohol use among Asians. *Alcohol Health Res World* 19:184–189
24. Pediconi M, Colombo C, Galli C (1985) Effects of acute and chronic alcohol administration on thromboxane and prostacyclin levels and release in rat brain cortex. *Prostaglandins* 30:313–322
25. Glowinski J, Iversen LL (1966) Regional studies of catecholamines in the rat brain: The disposition of [³H] Norepinephrine, [³H] DOPA in various regions of the brain. *J Neurochem* 13:655–669
26. Paulose CS, Dakshinamurthi K, Packer L, Stephens NL (1988) Sympathetic stimulation and hypertension in pyridoxine deficient adult rat. *Hypertension* 11:387–391
27. Unis AS, Micheal DR, Rene R, James HA, Daniel MD (1998) Ontogeny of human brain dopamine receptors I. Differential expression of [3H]-SCH23390 and [3H]-YM-09151-2 specific binding. *Dev Brain Res* 106:109–117
28. Scatchard G (1949) The attraction of proteins for small molecules and ions. *Ann NY Acad Sci* 660–672
29. Seglen PO (1971) Preparation of isolated rat liver cells. In: Prescott DM (ed) *Methods in cell biology*. Academic Press, New York, pp 29–83
30. Gill K, Amit Z, Smith BR (1996) The regulation of alcohol consumption in rats: the role of alcohol-metabolising enzymes—catalase and aldehyde dehydrogenase. *Alcohol* 13:347–353
31. Lowry OH, Roserbrough NJ, Farr AL, Randall RJ (1951) Protein measurements and folin phenol reagent. *J Biol Chem* 193:265–275
32. Konishi T, Calvillo M, Leng AS, Lin KM, Wan YJ (2004) Polymorphisms of the dopamine D₂ receptor, serotonin

- transporter, and GABA (A) receptor beta(3) subunit genes and alcoholism in Mexican-Americans. *Alcohol* 32:45–52
33. Pierce RC, Kalivas PW (1997) A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. *Brain Res Rev* 25:192–216
 34. Robinson TE, Berridge KC (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. *Brain Res Rev* 18:247–291
 35. Sari Y, Bell RL, Zhou FC (2006) Effects of chronic alcohol and repeated deprivations on dopamine D1 and D2 receptor levels in the extended amygdala of inbred alcohol-preferring rats. *Alcohol Clin Exp Res* 30:46–56
 36. Broadbent J, Kampmueller KM, Koonse SA (2005) Role of dopamine in behavioral sensitization to alcohol in DBA/2 J mice. *Alcohol* 35:137–148
 37. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Comings DE (1995) Dopamine D₂ receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. *Pharmacogenetics* 5:121–141
 38. Finckh U (2001) The dopamine D₂ receptor gene and alcoholism. Association studies. In: Agarwal DP, Seitz HK (eds) *Alcohol in health and disease*. Marcel Dekker, Inc., New York, pp 151–176
 39. Lu RB, Lee JF, Ko HC, Lin WW (2001) Dopamine D₂ receptor gene (DRD2) is associated with alcoholism with conduct disorder. *Alcohol Clin Exp Res* 25:177–184
 40. Noble EP (2000) The DRD₂ gene in psychiatric and neurological disorders and its phenotypes. *Pharmacogenomics* 1:309–333
 41. Laine TP, Ahonen A, Torniainen P, Heikkilä J, Pyhtinen J, Rasanen P, Niemela O, Hillbom M (1999) Dopamine transporters increase in human brain after alcohol withdrawal. *Mol Psychiatry* 4:189–191
 42. Socaransky SM, Aragon CM, Amit Z, Blander A (1984) Higher correlation of alcohol consumption with brain than liver aldehyde dehydrogenase in three strains of rats. *Neurosci Lett* 84:250–253
 43. Akash KG, Balarama KS, Paulose CS (2008) Enhanced 5-HT_{2A} receptor status in the hypothalamus and corpus striatum of ethanol treated rats. *Cell Mol Neurobiol* doi:10.1007/s10571-008-9281-2
 44. Airaksinen MM, Saano V, Steidel E, Juvonen H, Huhtikangas A, Gynther J (1984) Binding of beta-carbolines and tetrahydroisoquinolines by opiate receptors of the delta-type. *Acta Pharmacol Toxicol (Copenh)* 55:380–385
 45. Liljequist S, Berggren U, Engel J (1981) The effect of catecholamine receptor antagonists on alcohol-induced locomotor stimulation. *J Neural Transm* 50:57–67
 46. Risinger FO, Dickinson SD, Cunningham CL (1992) Haloperidol reduces alcohol-induced motor activity stimulation but not conditioned place preference. *Psychopharmacology* 107:453–456
 47. Shen EH, Crabbe JC, Phillips TJ (1995) Dopamine antagonist effects on locomotor activity in naive and alcohol-treated FAST and SLOW selected lines of mice. *Psychopharmacology* 118:28–36
 48. Jackson J, Paulose CS (1999) Enhancement of [*m*-methoxy 3H]MDL100907 binding to 5HT_{2A} receptors in cerebral cortex and brain stem of streptozotocin induced diabetic rats. *Mol Cell Biochem* 199(1–2):81–85
 49. Tabakoff B, Melchior C, Urwyler S, Hoffman PL (1980) Alterations in neurotransmitter function during the development of alcohol tolerance and dependence. *Acta Psychiatr Scand Suppl* 286:153–160
 50. Kerfoot SM, DMello C, Nguyen H, Ajuebor MN, Kubes P, Le T, Swain MG (2006) TNF-alpha-secreting monocytes are recruited into the brain of cholestatic mice. *Hepatology* 43:154–162
 51. Tarter RE, Arrie A, Van Thiel DH (1993) Liver-brain interactions in alcoholism. In: Hunt WA, Nixon SJ (eds) *Alcohol-Induced Brain Damage*. NIAAA Research Monograph, vol 22. National Institute on Alcohol Abuse and Alcoholism, Rockville, MD, pp 415–429
 52. Rivier C, Lee S (1996) Acute alcohol administration stimulates the activity of hypothalamic neurons that express corticotropin-releasing factor and vasopressin. *Brain Res* 726:1–10
 53. Galter D, Buervervenich S, Carmine A, Anvert M, Olson L (2003) ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia. *Neurobiol Dis* 14:637–647
 54. Kharchenko NK, Synyts'kyi VN, Kovtun TV (2001) Comparative analysis of the effects of alcoholism and opium addiction on liver function. *Fiziol Zh* 47:81–86
 55. George AK, Balarama KB, Paulose CS (2007) Decreased dopamine D2 receptor function in cerebral cortex and brain stem: their role in hepatic ALDH regulation in ethanol treated rats. *Mol Cell Biochem* 304:181–188
 56. Fogel WA, Andrzejewski W, Maslinski C (1991) Liver damage, voluntary alcohol intake and brain histamine. *Inflamm Res* 33:150–153
 57. Sudha B, Paulose CS (1997) Induction of DNA synthesis in primary cultures of rat hepatocytes by serotonin: Possible involvement of serotonin S2 receptor. *Hepatology* 27:62–67
 58. Biju MP, Pyroja S, Rajeshkumar NV, Paulose CS (2002a) Brain stem GABA receptor functional regulation during rat liver cell proliferation. *Neurochem Res* 27:905–910
 59. Pyroja S, Joseph B, Paulose CS (2007) Increased 5-HT (2C) receptor binding in the brain stem and cerebral cortex during liver regeneration and hepatic neoplasia in rats. *J Neurol Sci* 254:3–8
 60. Balarama Kaimal S, Gireesh G, Paulose CS (2007) Decreased GABAA receptor function in the brain stem during pancreatic regeneration in rats. *Neurochem Res* 32(11):1813–1822
 61. Shankar PN, Joseph A, Paulose CS (2007) Decreased [³H] YM-09151-2 binding to dopamine D2 receptors in the hypothalamus, brainstem and pancreatic islets of streptozotocin-induced diabetic rats. *Eur J Pharmacol* 28:99–105
 62. Jacek W, Krystyna G, Wladyslawa AD (2007) The regulation of liver cytochrome P450 by the brain dopaminergic system. *Curr Drug Metab* 8:631–638
 63. Aiko T, Gozoh T, Kiyohiko K, Keitaro H (1986) Developmental alteration in adrenergic regulation of hepatic glycogen phosphorylase. *Jpn J Pharmacol* 40:161–168
 64. Renuka TR, Robinson R, Paulose CS (2006) Increased insulin secretion by muscarinic M1 and M3 receptor function from rat pancreatic islets in vitro. *Neurochem Res* 31(3):313–320
 65. Biju MP, Pyroja S, Rajeshkumar NV, Paulose CS (2002b) Enhanced GABA(B) receptor in neoplastic rat liver: induction of DNA synthesis by baclofen in hepatocyte cultures. *J Biochem Mol Biol Biophys* 6(3):209–214
 66. Das VA, Robinson R, Paulose CS (2006) Enhanced beta-adrenergic receptors in the brain and pancreas during pancreatic regeneration in weanling rats. *Mol Cell Biochem* 289(1–2):11–19